|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1050 K STREET, NW, #800 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sarah J. Walsh, Vice President, Federal Government Relations Tax and Pharmaceuticals |
Date | 01/18/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.J. Res. 117 - Fiscal 2013 Continuing Appropriations Resolution, provisions relating to FDA funding, Vaccine Section 317 program, Ryan White CARE Act, BARDA funding, ACA implementation funding, 340B, IPAP
H.R. 2693 - Budget Control Act of 2011, sequestration implementation
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 741 - To amend the Federal Food, Drug and Cosmetic Act to prohibit the marketing of authorized generic drugs, provisions relating to authorized generics
H.R. 3995 - Protect Consumer Access to Generic Drugs Act, provisions related to patent settlements
H.R. 6621 - A bill to make technical corrections to the America Invents Act
S. 27 - Preserve Access to Affordable Generics Act, provisions related to patent settlements
S. 373 - The Fair Prescription Drug Competition Act, provisions related to authorized generics
S. 1882 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements
International intellectual property issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Gary |
Heimberg |
|
|
|
Kimberly |
Williams |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1513 and S.810 - Great Ape Protection and Cost Savings Act, provisions related to pre-clinical testing
H.R. 1930 and S. 1799 - Access to Appropriate Immunizations for Veterans Act of 2011, provisions related to extending VA performance measure to include all federally recommended vaccine
H.R. 2245, S. 296 - Preserving Access to Life-Savings Medicines Act of 2011, provisions related to drug shortages
H.R. 2405 and S. 1855 - Pandemic and All Hazards Preparedness Act, provisions relating to influenza vaccine innovative technologies
H.R. 2529 and S. 1368 - Restoring Access to Medication Act, provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
H.R. 2674 - 340B Program Improvement Act, provisions related to the 340B program
H.R. 4132 - FAST Act, provisions related to accelerated approval and other FDA matters
H.R. 4156 amd S. 2281 - Expanding and Promoting Expertise in Rare Treatments Act of 2012, provisions related to strengthening the FDA's ability to seek advice from external experts regarding rare diseases
H.R. 4223 and S. 1002 - Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act (SAFE DOSES), provisions related to supply chain security
H.R. 4274 - BPCA and PREA Reauthorization Act of 2012, Provisions related to amending title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act
H.R. 5651 - Food and Drug Administration Reform Act of 2012, provisions related to user fee reauthorization and FDA reform
H.R. 6190 - Asthma Inhalers Relief Act of 2012, provisions relating to the removal of Essential-Use Designation for epinephrine
H.R. 6611 - Patients Access to Drugs in Shortage Act of 2012, provisions to promote public notification and provide incentives to reduce drug shortages
S. 1584 - Drug Safety and Accountability Act of 2011, provisions related to drug safety
S. 1699- Prescription Drug Cost Reduction Act, provisions related to 340B and drug rebates
S. 1752 - Freedom to Breath Act of 2011, provisions relating to the removal of Essential-Use Designation for epinephrine
S. 2113 - Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act, provisions related to accelerated approval and other FDA matters
S. 2236 - Advancing Breakthrough Therapies for Patients Act of 2012, provisions related to FDA regulation
S. 2281 - Expanding and Promoting Expertise in Rare Treatments Act, provisions related to FDA regulation
S. 2289 - The Better Pharmaceuticals and Devices for Children Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act with respect to pediatric provisions
S. 3187 - Food and Drug Administration Safety and Innovation Act of 2012, provisions related to user fee reauthorization and FDA reform
PL 111-148, PL 111-152 - Patient Protection and Affordable Care Act, ACA implementation, Independent Payment Advisory Board (IPAB), comparative effectiveness, health information technology, disease prevention/wellness, sunshine and innovation
provisions
Federal Food, Drug, and Cosmetic Act, section related to FDA and regulation of nicotine replacement therapies
Comparative effectiveness policy issues
H.R. 6687, To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the definition of
taxable vaccines
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Gary |
Heimberg |
|
|
|
Kimberly |
Williams |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 5 - Protecting Access to Healthcare Act, provisions related to Independent Payment Advisory Board (IPAB)
H.R. 8 - American Taxpayer Relief Act of 2012, provisions related to Medicare and tax
H.R. 452 - Medicare Decisions Accountability Act, provisions related to the Independent Payment Advisory Board (IPAB)
H.R. 999 - Medicare Prescription Drug Savings and Choice Act of 2011, provisions related to Medicare Part D
H.R. 1063 - Strengthening Medicare & Repaying Taxpayers Act of 2011, provisions relating to reform of Secondary Payer rules
H.R. 1845 - Medicare IVIG Access Act, provisions relating to reform of Secondary Payer rules
H.R. 2190 - Medicare Drug Savings Act of 2011, provisions related to Medicare Part D
S. 365- Budget Control Act of 2011, Deficit reduction issues related to Medicare and Medicaid
S. 668 - Health Care Bureaucrats Elimination Act, provisions related to the Independent Payment Advisory Board (IPAB)
S. 1206 - Medicare Prescription Drug Savings Act of 2011, provisions related to Medicare Part D
S. 1251 - Medicare and Medicaid FAST Act, provisions related to Part D issues
S. 1699 - Prescription Drug Cost Reduction Act, provisions related to Medicare Part B and drug rebates
Dual eligibles coordination policy issues
Deficit reduction policy issues
Medicaid program, Covered Outpatient Drugs rulemaking
Medicare, Medicaid, Children's Health Insurance Programs,; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
Sarah |
Walsh |
|
|
|
Gary |
Heimberg |
|
|
|
Kimberly |
Williams |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 942 - American Research and Competitiveness Act of 2011, provisions relating to the research and development tax credit
S. 3144 - Temporary duty suspension for Preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading 2106.90.99)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Del Giorno |
|
|
|
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Gary |
Heimberg |
|
|
|
Kimberly |
Williams |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 6083 - Federal Agriculture Reform and Risk Management Act of 2012, provisions related to WTO Brazil Cotton dispute
H.R. 6156 - Russia and Moldova Jackson-Vanik Repeal and Sergei Magnistsky Rule of Law Accountability Act of 2012
S. 3240 - Agriculture Reform, Food and Jobs Act of 2012, provisions related to WTO Brazil cotton dispute
S. 3285 - A bill to authorize the extension of nondiscriminitory treatment (normal trade relations)to products of the Russian Fed.
Trans-Pacific Strategic Economic Partnership Agreement (TPP), provisions related to intellectual property, market access and public health
Mexico and Canada IP and market access issues in context of invitation to join TPP negotiations
EU/US trade liberalizing agreement
International market access and intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), U.S. Trade Representative (USTR), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Stephen |
Scango |
|
|
|
Shira |
Kilcoyne |
|
|
|
Edyta |
Weisner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |